Imfinzi (Durvalumab) is one of the most advanced immunotherapy treatments developed in recent years. It has given new hope to cancer patients worldwide thanks to its effectiveness in treating several types of cancer, including lung and bladder cancers.
What is Imfinzi?
Imfinzi belongs to the class of immunotherapy drugs and is classified as a PD-L1 inhibitor. It works by blocking the PD-L1 protein used by cancer cells to evade the immune system, enabling the body’s natural defenses to attack and destroy cancer cells more effectively.
Indications
-
Non-small cell lung cancer (NSCLC).
-
Small cell lung cancer (SCLC).
-
Urothelial carcinoma (bladder cancer).
-
Other indications under clinical investigation.
Administration
Imfinzi is given as an intravenous infusion, with doses determined by the treating physician according to the patient’s condition and response.
Common Side Effects
-
Fatigue.
-
Nausea or appetite loss.
-
Cough or shortness of breath.
-
Immune or liver-related complications.
Availability and Price in Egypt
Imfinzi is available in Egypt through major hospitals and specialized oncology centers. Its price is relatively high, similar to other leading immunotherapy drugs such as Keytruda and Opdivo, depending on the required dose and treatment plan.
Conclusion
Imfinzi (Durvalumab) represents a modern and powerful treatment option, especially for lung and bladder cancer patients, by harnessing the immune system to fight cancer cells effectively.
